Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edgewise Therapeutics, Inc. filings document a late-stage clinical biopharmaceutical company developing treatments for severe muscle diseases, including programs for muscular dystrophies and serious cardiac conditions. Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical-program disclosures, and material governance events.
The company’s proxy materials describe board structure, director elections, executive compensation, equity-award information, stockholder voting matters, and governance practices. Other disclosed matters include officer appointments, director appointments, compensatory arrangements, exhibits to earnings releases, and operating context for a development-stage drug pipeline.
Edgewise Therapeutics, Inc. reported that Chief Financial Officer Michael Nofi received a grant of 48,750 stock options on August 12, 2026. These options have an exercise price of $43.56 per share, reflecting the fair market value on the grant date, and expire on August 12, 2036. The amendment clarifies that an earlier filing incorrectly showed a $0.00 exercise price due to a clerical error. According to the vesting terms, 1/48 of the options vest each month beginning on September 12, 2026, contingent on his continued service.
Edgewise Therapeutics, Inc. reported an amended insider transaction for its CMO, Joanne M. Donovan. She received a grant of 65,000 stock options to purchase common stock at an exercise price of $43.56 per share, expiring on August 12, 2036. The company states this amendment corrects a clerical error in the originally reported exercise price. The options vest in equal monthly installments over four years starting on September 12, 2026, contingent on her continued service.
Edgewise Therapeutics, Inc. reported that Chief Scientific Officer Alan J. Russell received a grant of stock options for 65,000 shares of common stock on August 12, 2026. An amendment corrects the option’s exercise price to $43.56 per share, reflecting the fair market value on the grant date.
The options have an expiration date of August 12, 2036. According to the vesting terms, 1/48 of the shares vest each month beginning September 12, 2026, contingent on Russell continuing as a service provider through each vesting date.
Edgewise Therapeutics, Inc. reported that its General Counsel, John R. Moore, received a grant of a stock option covering 65,000 shares of common stock. The option has a corrected exercise price of $43.56 per share, reflecting the fair market value on the grant date, and expires on August 12, 2036. According to the vesting terms, 1/48th of the shares vest each month beginning on September 12, 2026, contingent on his continued service.
Edgewise Therapeutics, Inc. reported that Chief Business Officer Behrad Derakhshan received a grant of 100,000 stock options to purchase common stock. This amendment corrects the option’s exercise price to $43.56 per share, reflecting the fair market value on the grant date. The options vest in 1/48 monthly installments beginning September 12, 2026, contingent on continued service, and expire on August 12, 2036. Following this grant, Derakhshan holds 100,000 derivative securities directly.
Edgewise Therapeutics, Inc. granted its Chief Financial Officer, Michael Nofi, new equity awards. 24,375 Restricted Stock Units were awarded for no additional cash consideration, each RSU representing one share of common stock, vesting in four equal annual installments starting August 12, 2027. In addition, a stock option for 48,750 shares of common stock with a stated exercise price of $0.0000 per share was granted, expiring August 12, 2036 and vesting as to 1/48 of the shares each month beginning September 12, 2026, subject to continued service.
Edgewise Therapeutics, Inc. CMO Joanne M. Donovan reported multiple equity transactions. On August 12, 2026, she exercised 12,812 Restricted Stock Units into common stock at $0.00 per share and received new awards of 32,500 RSUs and 65,000 stock options, each for no additional cash consideration. The options cover 65,000 shares of common stock and vest in 48 equal monthly installments beginning September 12, 2026. On August 12–13, 2026, she sold a total of 9,441 shares of common stock at average prices between $43.12 and $44.57 per share. Footnotes state that 2026-08-12 sales were executed as "sell-to-cover" transactions to satisfy statutory tax withholding on RSU vesting, and the August 13 sale of 2,919 shares was made under a pre-arranged Rule 10b5-1 Plan adopted on December 26, 2025.
Edgewise Therapeutics, Inc. Chief Scientific Officer Alan J. Russell reported multiple equity transactions on August 12, 2026. He exercised previously granted Restricted Stock Units into 5,781 and 7,031 shares of common stock, then sold a total of 5,901 shares in market transactions solely to cover statutory tax-withholding obligations under a "sell-to-cover" arrangement, which the company describes as not a discretionary sale. He also received new equity awards: 32,500 RSUs that vest in four equal annual installments beginning August 12, 2027, and a stock option for 65,000 shares, vesting 1/48th monthly starting September 12, 2026.
Edgewise Therapeutics, Inc. General Counsel John R. Moore reported a mix of equity transactions on August 12, 2026. He exercised Restricted Stock Units into 12,499 shares of common stock and sold 5,016 shares in a sell‑to‑cover transaction to satisfy statutory tax withholding obligations. He also received new awards of 32,500 Restricted Stock Units vesting annually beginning August 12, 2027, and a stock option covering 65,000 shares, vesting monthly beginning September 12, 2026.
Edgewise Therapeutics, Inc. reported that Chief Business Officer Derakhshan Behrad had RSUs for 5,781 and 7,500 shares convert into common stock on August 12, 2026. A total of 5,100 shares were sold in multiple trades to cover statutory tax withholding obligations under a sell-to-cover arrangement, which the company states was not a discretionary sale. Behrad also received equity awards of 50,000 RSUs, vesting in four annual installments beginning August 12, 2027, and a stock option for 100,000 shares vesting monthly over 48 months beginning September 12, 2026.